Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

Journal of Thoracic Oncology

Volumn 8, Issue 3, 2013, Pages 346-351

  Yu, Helena A ^a   Sima, Camelia S ^c   Huang, James ^b   Solomon, Stephen B ^c   Rimner, Andreas ^d   Paik, Paul ^a   Pietanza, M Catherine ^a   Azzoli, Christopher G ^a   Rizvi, Naiyer A ^a   Krug, Lee M ^a   Miller, Vincent A ^a   Kris, Mark G ^a   Riely, Gregory J ^a  

^a Gastrointestinal Oncology Solid Tumor Service   (United States)

^b Thoracic Service   (United States)

^c Department of Epidemiology and Biostatistics ^*  (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors; EGFR mutant lung cancer; Local therapy; Metastasectomy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; FEMALE; HUMAN; LOBECTOMY; LOCAL THERAPY; LUNG BIOPSY; LUNG CANCER; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME;

EID: 84874065941     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827e1f83     Document Type: Article

References (42)

1. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101: 13306-13311.
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448: 561-566.
3. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131: 1190-1203.
4. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18: 375-377.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-2139.
6. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
7. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: 947-957.
8. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11: 121-128.
9. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-2388.
10. Rosell R, Carcereny E, Gervais R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13: 239-246.
11. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012;13: 539-548.
12. Jänne PA, Wang X, Socinski MA, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012;30: 2063-2069.
13. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3: 75ra26.
14. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352: 786-792.
15. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316: 1039-1043.
16. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104: 20932-20937.
17. Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006;355: 213-215.
18. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFRmutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3: 90ra59.
19. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17: 6298-6303.
20. Goldberg SB, Oxnard GE, Digumarthy S, et al. Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI). J Clin Oncol 2012: 30 (suppl; abstr 7524).
21. Downey RJ. Surgery for colorectal and sarcomatous pulmonary metastases: history, current management, and future directions. Thorac Surg Clin 2006;16: 133-7, v.
22. Russo P, O'Brien MF. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol Clin North Am 2008;35: 679-86; viii.
23. NCCN clinical practice guidelines in oncology: Kidney Cancer. National Comprehensive Cancer Network. (Accessed March 27, 2012, at http://www.nccn.org/ professionals/physician-gls/pdf/kidney.pdf.)
24. NCCN clinical practice guidelines in oncology: Colon Cancer. National Comprehensive Cancer Network. (Accessed March 27, 2012, at http://www.nccn.org/ professionals/physician-gls/pdf/colon.pdf.)
25. NCCN clinical practice guidelines in oncology: Soft Tissue Sarcoma. National Comprehensive Cancer Network. (Accessed March 27, 2012, at http://www.nccn.org/professionals/physician-gls/pdf/sarcoma.pdf.)
26. Pfannschmidt J, Hoffmann H, Dienemann H. Reported outcome factors for pulmonary resection in metastatic colorectal cancer. J Thorac Oncol 2010;5(6 Suppl 2):S172-S178.
27. Ríos A, Galindo PJ, Torres J, et al. Factors causing early relapse after lung metastasis surgery. Eur J Cancer Care (Engl) 2007;16: 26-32.
28. Younes RN, Fares AL, Gross JL. Pulmonary metastasectomy: a multivariate analysis of 440 patients undergoing complete resection. Interact Cardiovasc Thorac Surg 2012;14: 156-161.
29. Casiraghi M, De Pas T, Maisonneuve P, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the "international registry of lung metastases". J Thorac Oncol 2011;6: 1373-1378.
30. Pfannschmidt J, Schlolaut B, Muley T, Hoffmann H, Dienemann H. Adrenalectomy for solitary adrenal metastases from non-small cell lung cancer. Lung Cancer 2005;49: 203-207.
31. Furák J, Troján I, Szöke T, et al. Lung cancer and its operable brain metastasis: survival rate and staging problems. Ann Thorac Surg 2005;79: 241-7; discussion 241.
32. Voltolini L, Rapicetta C, Luzzi L, et al. Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup. Eur J Cardiothorac Surg 2010;37: 1198-1204.
33. Yano T, Haro A, Yoshida T, et al. Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol 2010;102: 852-855.
34. Downey RJ, Ng KK, Kris MG, et al. A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung Cancer 2002;38: 193-197.
35. Oxnard GR, Lo P, Jackman DM, et al. Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer. J Clin Oncol 2012: 30 (suppl; abstr 7547).
36. Faehling M, Eckert R, Kamp TG, et al. Treatment with EGFR tyrosine kinase inhibitors beyond progression in long-term responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival. J Clin Oncol 2012: 30 (suppl; abstr 7572).
37. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008;3: 111-116.
38. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17: 1616-1622.
39. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
40. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351: 125-135.
41. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366: 883-892.
42. Vignot S, Frampton G, Yelensky R, et al. Concordance of driver mutations in primary and matched metastasis from patients with non-small cell lung cancer (NSCLC) using next-generation sequencing (NGS). J Clin Oncol 2012: 30 (suppl; abstr 7529).